LISATA THERAPEUTICS, INC. 8-K

What Happened
Lisata Therapeutics, Inc. (the “Company”) filed an 8-K disclosing an amendment to its Agreement and Plan of Merger with Kuva Labs Inc. (Parent) and Kuva Acquisition Corp. (Purchaser). The Amendment, dated July 16, 2026 and attached as Exhibit 2.1, extends the Merger Agreement’s Outside Date from July 17, 2026 to July 21, 2026. The filing also references the related tender offer statement on Schedule TO (filed by Parent and Purchaser) and the Company’s Solicitation/Recommendation Statement on Schedule 14D-9.

Key Details

• Amendment date: July 16, 2026; Outside Date extended from July 17, 2026 to July 21, 2026.
• Amendment is filed as Exhibit 2.1 to the Form 8-K.
• Parent/Purchaser filed a Schedule TO (tender offer) and Lisata filed a Schedule 14D-9 (solicitation/recommendation).
• Investors can obtain the tender offer and solicitation documents free at www.sec.gov or via Lisata’s Investors page (lisata.com).

Why It Matters
The short, four-day extension gives the parties additional time to complete the pending merger/tender offer process. For shareholders, the filing is a reminder to review the Schedule TO and Lisata’s Schedule 14D-9—these documents contain the full terms, conditions and the Company’s recommendation and are important before deciding whether to tender shares. The 8-K does not disclose other changes to deal terms beyond the Outside Date extension; the full Amendment text should be reviewed for complete details.